Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE Trial
Circulation · 06.01.2026 · 153 (1) · 21-34
DOI: 10.1161/circulationaha.125.077232 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation, erschienen am 06.01.2026. Verfasst von Robert A Lookstein und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Inverventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (R.A.L.). Hauptthemen laut MEDLINE: Anticoagulants, Pulmonary Embolism, Thrombectomy. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Penumbra.
Abstract (Originalsprache)
BACKGROUND: Patients with intermediate-high risk pulmonary embolism (PE) have an elevated right ventricular (RV) to left ventricular (LV) diameter ratio and are at risk of early clinical decompensation and mortality. Reperfusion therapy aims to rapidly relieve acute RV pressure overload and to normalize hemodynamics. STORM-PE (A Prospective, Multicenter, Randomized Controlled Trial Evaluating Anticoagulation Alone Versus Anticoagulation Plus Mechanical Aspiration With the Indigo Aspiration System for the Treatment of Intermediate-High Risk Acute Pulmonary Embolism) is the first reported randomized controlled trial to test the efficacy and to evaluate the safety of mechanical thrombectomy, specifically computer-assisted vacuum thrombectomy (CAVT) with anticoagulation compared to anticoagulation alone. METHODS: STORM-PE is an international randomized controlled trial with 1:1 randomization to CAVT with anticoagulation or anticoagulation alone. Eligible adults had acute-onset (symptoms ≤14 days), intermediate-high risk PE and were normotensive, with an RV/LV ratio ≥1.0 on computed tomographic pulmonary angiography and elevated cardiac biomarkers. The primary end-point analysis tested for a difference between groups for the change in RV/LV ratio at 48 hours, assessed by a blinded independent imaging core laboratory. Secondary end points included major adverse events within 7 days (a composite of clinical deterioration necessitating rescue therapy, PE-related mortality, symptomatic recurrent PE, and major bleeding), adjudicated by an external clinical events committee. Additional outcomes included change in vital signs and core laboratory–assessed pulmonary artery obstruction at 48 hours. RESULTS: A total of 100 patients enrolled across 22 sites were randomized to CAVT (n=47) or anticoagulation alone (n=53). Baseline characteristics were comparable between arms. At 48 hours, mean reduction in RV/LV ratio was greater for CAVT (0.52±0.37) than anticoagulation (0.24±0.40), a difference of 0.27 (95% CI, 0.12–0.43; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Inverventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (R.A.L.).
- Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany (S.V.K.).
- Department of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece (S.V.K.).
- Vascular Medicine, Massachusetts General Brigham, Boston (I.W.).
- Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA (S.Y.D.).
- Interventional Cardiology, Baylor University Medical Center, The Heart Hospital, Dallas, TX (Z.R.).
ORCID-Profile: Robert A Lookstein, Stavros V Konstantinides, Ido Weinberg, Suhail Y Dohad, Zachary Rosol, John M Moriarty, Sahil A Parikh, Andrew Holden, Richard N Channick, Khanjan H Nagarsheth, Rachel P Rosovsky
Förderung
- Penumbra
Zitieren
APA
Lookstein, R. A., Konstantinides, S. V., Weinberg, I., Dohad, S. Y., Rosol, Z., Kopeć, G., Moriarty, J. M., Parikh, S. A., Holden, A., Channick, R. N., McDonald, B., Nagarsheth, K. H., Yamada, K., Rosovsky, R. P., & STORM-PE Trial Investigators (2026). Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE Trial. Circulation, 153(1), 21-34. https://doi.org/10.1161/circulationaha.125.077232
Vancouver
Lookstein RA, Konstantinides SV, Weinberg I, Dohad SY, Rosol Z, Kopeć G, et al. Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE Trial. Circulation. 2026;153(1):21-34. doi:10.1161/circulationaha.125.077232
BibTeX
@article{Lookstein2026,
author = {Lookstein, Robert A and Konstantinides, Stavros V and Weinberg, Ido and Dohad, Suhail Y and Rosol, Zachary and Kopeć, Grzegorz and Moriarty, John M and Parikh, Sahil A and Holden, Andrew and Channick, Richard N and McDonald, Braedon and Nagarsheth, Khanjan H and Yamada, Kei and Rosovsky, Rachel P and STORM-PE Trial Investigators, STORM-PE Trial Investigators},
title = {Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE Trial},
journal = {Circulation},
year = {2026},
volume = {153},
number = {1},
pages = {21--34},
doi = {10.1161/circulationaha.125.077232}
}
EUVIMED